Sustainability & Impact
One Health
Since inception, ARCHIMED’s philosophy has been shaped by the belief that the health of humans, animals, and the environment is deeply interconnected. All our funds make investments through this “One Health” lens, partnering with companies that aim to fundamentally improve human, animal, and environmental health outcomes. ARCHIMED has three funds – MED III, MED Platform II, and MED Rise – with investments that contribute positively to relevant United Nations Sustainable Development Goals (UN SDGs) and at least one of our Health Objectives:
- Better Efficacy: the capability of a product or treatment to consistently produce the intended health benefit or therapeutic effect.
- Better Efficiency: the ability to manufacture a product or deliver a service at a faster speed and/or reduced cost, without compromising quality or desired outcomes.
- Better Safety: the prevention of unintended harm during the provision of products or services, prioritizing human, animal, and/or environmental well-being.
- Better Accessibility: the ease with which products and services are available and within the reach of all stakeholders in need.
- Better Affordability: the extent to which a product or service is financially accessible to stakeholders in need, considering their ability to pay.
OUR SUSTAINABILITY DISCLOSURES
Our Health Objectives help us define each investment’s impact potential in solving global healthcare challenges recognized by international organizations like the UN, the World Health Organization (WHO), the World Organization for Animal Health (WOAH), and Food and Agriculture Organization (FAO).
HEALTH CHALLENGES ADDRESSED BY OUR COMPANIES
“ARCHIMED was pivotal to triggering our ESG journey, which has enabled DIESSE to align its operations and processes with the 2030 agenda for sustainable development. The nature of what we do, healthcare for patients, and our commitment to a better world have naturally led us to change our status to become a Benefit Corporation. Moreover, ARCHIMED shared with us the vision to build the DIESSE Biotech Campus, the most advanced and fully sustainable R&D and production biotech plant for the In Vitro Diagnostics in Europe.”
Massimiliano Bogetti
CEO, DIESSE
“With the support of ARCHIMED, so far, we have trained ~4k healthcare professionals through the Natus Academy and have screened or treated over 90 million patients. By providing high quality medical equipment for diagnosis and screening, we are enabling better safety for patients while also enhancing efficiency for hospitals, drastically improving health outcomes at both levels.”
David Milne
Natus Sensory Division, Chief Human Resources Officer
Contribution to SDG targets
Our companies support human, animal, and environmental well-being, by providing healthcare products and services that contribute to the attainment of SDG 3 targets.
Over 12M
patients served annually through our companies’ healthcare solutions.
Our companies foster scientific innovation by advancing research and development of cutting-edge sustainable healthcare solutions that contribute to the attainment of SDG 9 targets.
Over 10%
of revenue is invested annually in R&D, on average across our companies.
